Nanox (NASDAQ: NNOX), a leader in innovative medical imaging technology, announced that its subsidiary, Nanox AI Ltd., has entered into a sales reseller agreement with Vertec Scientific Ltd. for the commercialization of its Nanox.AI bone solution, HealthOST, in the United Kingdom. The agreement grants Vertec an exclusive license to market and resell HealthOST in the UK, subject to minimum annual license commitments, for an initial three-year term.
HealthOST is an FDA-cleared and UKCA/CE-marked AI software solution that analyzes eligible routine CT scans to support clinicians in evaluating and assessing musculoskeletal disease of the spine, including osteoporosis. This technology addresses a critical healthcare need, as osteoporosis often goes undetected until a fracture occurs. By leveraging routine CT scans, HealthOST enables opportunistic screening without additional radiation exposure or patient visits, potentially improving early detection and reducing the burden of osteoporotic fractures on the healthcare system.
The significance of this agreement is underscored by the recent recommendation from the National Institute for Health and Care Excellence (NICE). In November 2025, NICE recommended HealthOST and a previous version, HealthVCF, among five AI technologies for National Health Service (NHS) use as options to aid opportunistic detection of vertebral fragility fractures. This endorsement is a major milestone, as NICE guidance often sets the standard for adoption within the NHS, potentially paving the way for widespread implementation across the UK.
The UK market presents a substantial opportunity for Nanox. With an aging population and increasing prevalence of osteoporosis, the demand for efficient diagnostic tools is growing. The NHS's commitment to integrating AI-driven solutions aligns with Nanox's vision of expanding access to preventive healthcare. By partnering with Vertec Scientific, a reputable distributor with established relationships in the UK healthcare sector, Nanox aims to accelerate the adoption of HealthOST and improve patient outcomes.
Vertec Scientific's expertise in medical device distribution and its existing network will be instrumental in navigating the UK's regulatory and procurement processes. The exclusive nature of the agreement, coupled with minimum annual license commitments, underscores Vertec's confidence in the product's potential and ensures a dedicated focus on driving sales.
This strategic move is part of Nanox's broader mission to transform healthcare through its integrated platform, which includes the Nanox.ARC imaging system, AI-based solutions, cloud-based software, and teleradiology services. The company's commitment to innovation is reflected in its portfolio, which aims to enhance clinical efficiency and broaden access to care.
For investors, this development signals Nanox's progress in commercializing its AI solutions beyond its home market. The NICE recommendation and the exclusive UK agreement could serve as a catalyst for further international expansion and revenue growth. As Nanox continues to execute its strategy, the successful deployment of HealthOST in the UK may set a precedent for other markets.
In summary, the reseller agreement with Vertec Scientific marks a significant step for Nanox in bringing its AI-powered bone health solution to the UK, leveraging NICE's endorsement to potentially transform osteoporosis screening in the NHS. This move not only expands Nanox's commercial footprint but also reinforces the value of AI in preventive healthcare.
